Achieve Life Sciences Inc Quick Ratio (ACHV) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Achieve Life Sciences Inc   (NASDAQ: ACHV)

Achieve Life Sciences Inc 's Quick Ratio

ACHV's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 1.65 below Achieve Life Sciences Inc average.

Within In Vitro & In Vivo Diagnostic Substances industry 7 other companies have achieved higher Quick Ratio than Achieve Life Sciences Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 956 to 1555.

Explain Quick Ratio?
How much Cash & cash equivalents ACHV´s has?
What are ACHV´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ACHV Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 2205.58 % 65.96 % 35.92 % 44.88 % -37.43 %
Y / Y Cash & cash equivalent Change 489.64 % 25.92 % 5.95 % 143.33 % -9.65 %
Quick Ratio MRQ 1.65 2.47 4.01 4.94 6.46
ACHV's Total Ranking # 1555 # 956 # 698 # 563 # 214
Seq. Current Liabilities Change 1570.39 % 30.29 % -6.66 % 13.5 % 20.24 %
Seq. Cash & cash equivalent Change 1016.01 % -19.6 % -24.34 % -13.15 % 138.32 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 8
Healthcare Sector # 543
Overall Market # 1555


Quick Ratio Statistics
High Average Low
12.12 4.57 0.72
(Sep 30 2020)   (Dec 31 2023)




Financial Statements
Achieve Life Sciences Inc 's Current Liabilities $ 198 Millions Visit ACHV's Balance sheet
Achieve Life Sciences Inc 's Cash & cash equivalent $ 327 Millions Visit ACHV's Balance sheet
Source of ACHV's Sales Visit ACHV's Sales by Geography


Cumulative Achieve Life Sciences Inc 's Quick Ratio

ACHV's Quick Ratio for the trailling 12 Months

ACHV Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 684.52 % 14.57 % -27.6 % -48.67 % -51.44 %
Y / Y Cash & cash equivalent TTM Growth 231.71 % 21.99 % -10.27 % -1.17 % -18.63 %
Quick Ratio TTM 1.93 4.31 4.73 5.02 4.56
Total Ranking TTM # 459 # 515 # 340 # 397 # 838
Seq. Current Liabilities TTM Growth 482.14 % 13.63 % 7.47 % 10.36 % -14.98 %
Seq. Cash & cash equivalent TTM Growth 160.33 % 3.69 % 1.27 % 21.35 % -4.27 %

Quick ratio ranking by company, industry and sector >> Back to ACHV Financial Strength Comparisons >> Go to Compare ACHV Quick Ratio to its Competitors

On the trailing twelve months basis Due to in Current Liabilities in the Q2 2026 to $197.66 millions, cumulative Quick Ratio decreased to 1.93 below the Achieve Life Sciences Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within In Vitro & In Vivo Diagnostic Substances industry 14 other companies have achieved higher Quick Ratio than Achieve Life Sciences Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 2698 to 3925.

Explain Quick Ratio?
How much Cash & cash equivalents ACHV´s has?
What are ACHV´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the In Vitro & In Vivo Diagnostic Substances Industry # 15
Healthcare Sector # 891
Within the Market # 1555


trailing twelve months Quick Ratio Statistics
High Average Low
10.14 3.27 0.5
(Dec 31 2020)   (Sep 30 2016)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within In Vitro & In Vivo Diagnostic Substances Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Qc Technologies Inc   3.00 $ 10.987  Millions$ 3.669  Millions
Alpha Teknova Inc   2.54 $ 17.436  Millions$ 6.872  Millions
Lantheus Holdings Inc   1.77 $ 593.298  Millions$ 335.677  Millions
Insight Molecular Diagnostics Inc   1.73 $ 17.756  Millions$ 10.286  Millions
Achieve Life Sciences Inc   1.65 $ 326.645  Millions$ 197.657  Millions
Immucell Corporation  1.51 $ 8.860  Millions$ 5.863  Millions
Myriad Genetics Inc   0.88 $ 115.200  Millions$ 130.700  Millions
Biomerica Inc   0.53 $ 1.308  Millions$ 2.481  Millions

Date modified: 2026-09-04T23:59:41+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.